Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Forte Biosciences, Inc.TOCA · Entity 9529 | EVP, Research & Pharm Devel | October 04, 2019 | October 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Forte Biosciences, Inc.
Report date October 04, 2019 · Filed October 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2029-10-03 | Direct | 12,500 |
Reported balance
After 2019-10-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-10-04 · Grant · Acquired 12,500 · Balance 12,500 F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 04, 2019 Filed Oct 5, 2019 00:40 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantEmployee Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052623 · doc4.xml · derivative · entry 1 Jolly Douglas · CIK 0001701643 · EVP, Research & Pharm Devel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:04 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016889 · doc4.xml · derivative · entry 1 Jolly Douglas · CIK 0001701643 · EVP, Research & Pharm Devel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: 25% of the shares vest on 3/1/2020 amd the balance of the shares vest monthly thereafter. Read SEC document |
| December 10, 2018 Filed May 29, 2019 20:32 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantCommon Stock | 732 | $8.19 | $5,995.08 |
DisclosureSEC source: 0001209191-19-033202 · doc4.xml · nonDerivative · entry 2 Jolly Douglas · CIK 0001701643 · EVP, Research & Pharm Devel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,478 F2 · kind: This Form 4 is being filed voluntarily to report the acquisition of 732 shares by the Reporting Person on December 10, 2018 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 08, 2018 Filed May 29, 2019 20:32 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantCommon Stock | 703 | $8.19 | $5,757.57 |
DisclosureSEC source: 0001209191-19-033202 · doc4.xml · nonDerivative · entry 1 Jolly Douglas · CIK 0001701643 · EVP, Research & Pharm Devel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,746 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 703 shares by the Reporting Person on June 8, 2018 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:19 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $11.19 | $0.00 |
DisclosureSEC source: 0001209191-18-015835 · doc4.xml · derivative · entry 1 Jolly Douglas · CIK 0001701643 · EVP, Research & Pharm Devel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-02-29 F1 · derivative.exercise_date: 1/4th of the shares vest one year after 3/01/2018; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 3/01/2018. Read SEC document |
| December 08, 2017 Filed Dec 15, 2017 01:46 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | OtherCommon Stock | 739 | $8.50 | $6,281.50 |
DisclosureSEC source: 0001209191-17-065786 · doc4.xml · nonDerivative · entry 1 Jolly Douglas · CIK 0001701643 · EVP, Research & Pharm Devel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,043 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 739 shares by the Reporting Person on December 8, 2017 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 26, 2017 Filed Jun 1, 2017 01:13 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantEmployee Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $16.32 | $0.00 |
DisclosureSEC source: 0001209191-17-036624 · doc4.xml · derivative · entry 1 Jolly Douglas · CIK 0001701643 · EVP, Research & Pharm Devel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-05-25 F1 · derivative.exercise_date: 1/4th of the shares vest one year after 5/26/2017; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 5/26/2017. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 01:04 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantEmployee Stock Option (right to buy) · Derivative | 14,492 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001209191-17-026753 · doc4.xml · derivative · entry 1 Jolly Douglas · CIK 0001701643 · EVP, Research & Pharm Devel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,492 Underlying: Common Stock · 14,492 shares Expires 2027-04-11 F1 · derivative.exercise_date: 1/4th of the shares vest one year after 4/1/2017; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 4/1/2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.